Oncology Briefings™: Exploring a New Wave of Progress in the Management of Neutropenia

Release Date: November 27, 2019
Expiration Date: November 27, 2020
Media: Internet - based

Activity Overview

Chemotherapy induced neutropenia (CIN) is a common adverse event associated with cancer treatment. CIN and its associated complications, including febrile neutropenia, can have serious, life-threatening effects on patients. In addition to an increased risk of infection and worsening of disease, CIN can negatively impact cancer therapy outcomes as chemotherapy dose reductions and delays are common management strategies.

This Oncology Briefings™ program will help clinicians acquire the knowledge to meet challenges associated with the management of CIN through a series of audio interviews with Jeffrey Crawford, MD, an expert in neutropenia, who will discuss guideline recommendations, prophylactic strategies, biosimilars, and novel and emerging agents to treat patients with cancer at risk for febrile neutropenia.

Benefits of Participating

• Apply insight from a leading expert investigator to clinical scenarios for patients at risk for developing chemotherapy-induced neutropenia
• Implement strategies to manage neutropenia with current agents and recognize emerging agents and novel strategies for reducing neutropenia
• Recognize important caveats to planning management strategies for complex cases
• Hone decision-making skills when considering treatment options for patients undergoing rigorous chemotherapy regimens in daily clinical practice

Acknowledgement of Commercial Support

This activity is supported by an educational grant from BeyondSpring Pharmaceuticals, Inc.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, fellows, surgical oncologists and radiation oncologists interested in treatment and management of patients with cancer. Nurse practitioners, nurses, physician assistants, researchers, and other healthcare professionals interested in the treatment of cancer may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Identify patients with cancer at low-, intermediate-, and high-risk of developing neutropenia, including febrile neutropenia.
• Discuss clinical evidence supporting the use of primary prophylaxis to help prevent and manage febrile neutropenia in patients with cancer.
• Analyze emerging data on novel agents exhibiting anti-neutropenic effects that can be used in the clinical management of neutropenia in patients with cancer.
• Develop effective management plans focused on pretreatment against neutropenia, and reactive approaches to treat patients when neutropenia occurs.

Faculty, Staff, and Planners’ Disclosures

Faculty

Jeffrey Crawford, MD
George Barth Geller Professor for Research in Cancer
Duke University Medical Center
Co-Director of the Solid Tumor Therapeutics Program
Duke Cancer Institute
Durham, NC

Disclosures: Principal Investigator/Institutional Research Funding: AstraZeneca, Genentech, Helsinn; Scientific Advisor: Amgen, AstraZeneca, Coherus, Enzychem, G1 Therapeutics, GlaxoSmithKline, Merck, Pfizer, Spectrum; Data and Safety Monitoring Board Member: Beyond Spring, G1 Therapeutics, Merrimack, Mylan, Roche.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.